Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation

Staatz, Christine E., Duffull, Stephen B., Kiberd, Bryce, Fraser, Albert D. and Tett, Susan E. (2005) Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. European Journal of Clinical Pharmacology, 61 7: 507-516. doi:10.1007/s00228-005-0927-4


Author Staatz, Christine E.
Duffull, Stephen B.
Kiberd, Bryce
Fraser, Albert D.
Tett, Susan E.
Title Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation
Journal name European Journal of Clinical Pharmacology   Check publisher's open access policy
ISSN 0031-6970
1432-1041
Publication date 2005-08-01
Sub-type Article (original research)
DOI 10.1007/s00228-005-0927-4
Volume 61
Issue 7
Start page 507
End page 516
Total pages 10
Editor R. Dahlqvist
Place of publication Berlin and New York
Publisher Springer-Verlag
Collection year 2005
Language eng
Subject 320500 Pharmacology and Pharmaceutical Sciences
320503 Clinical Pharmacology and Therapeutics
C1
730115 Urogenital system and disorders
Abstract Objective To investigate the population pharmacokinetics of mycophenolic acid (MPA) in adult kidney transplant recipients during the crucial first week after transplantation. Methods Data were collected from 117 patients. MPA plasma concentrations were determined at t=0, 1, 2, 3 and 4 h after mycophenolate mofetil dosing on days 3, 5 and 7. Population analysis was performed using NONMEM. Covariates screened were sex, age, body weight, serum creatinine, creatinine clearance, serum albumin, days of therapy, diabetes mellitus, organ source (live or cadaveric) and co-therapy (tacrolimus or cyclosporine). Final model validity was evaluated using 200 bootstrapped samples from the original data. Bias and precision were determined through comparison of observed and predicted concentrations. Results Individual concentration–time profiles showed evidence of an absorption lag time and enterohepatic recirculation of MPA in some patients on some occasions. The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%). CL/F decreased significantly with increasing serum albumin (1.42 l/h reduction in total plasma CL/F with each 1 g/l increase in albumin) and was 27% greater in patients receiving cyclosporine than in those receiving tacrolimus. Evaluation of the final model showed close agreement between pairs of bootstrapped and final model parameter estimates (all differences <7%). Predictions were non-biased (0.11 mg/l) but imprecise (2.8 mg/l). Conclusion Population pharmacokinetic parameters for MPA were determined. These can be used to achieve specific target MPA concentrations or areas under the concentration–time curve.
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2006 Higher Education Research Data Collection
School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 41 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 46 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 21 Dec 2007, 12:22:11 EST by Laura McTaggart on behalf of School of Pharmacy